Recently, imiquimod and TMX-202 (TLR7 agonists) were tested for bladder cancer immunotherapy, while CpG ODN (a TLR9 agonist) and HP-NAP (a TLR2 agonist) demonstrated reduced tumor growth in an MB49 bladder cancer mouse model [161,162,163,164]. Here, TLR7 is linked to urinary bladder cancer.